Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort

Cottez, Rosalie J. ; Peyrot, Clémence ; Denis, Hélèna L. ; Tremblay, Cyntia ; Loiselle, Andréanne ; Dallaire-Théroux, Caroline ; Filali-Mouhim, Ali ; Hébert, Sébastien S. ; Leclerc, Nicole and Blennow, Kaj LU , et al. (2026) In Alzheimer's and Dementia 22(6).
Abstract

INTRODUCTION: We evaluated associations between phosphorylated au 217 (p-tau217), p-tau181, p-tau231, and vascular risk factors with cognitive outcomes across the Alzheimer's disease (AD) continuum. METHODS: Baseline plasma p-tau concentrations and vascular risk factors were assessed in 277 Consortium for the Early Identification of Alzheimer's Disease–Quebec (CIMA-Q) participants. Associations between these markers, cognition, and clinical progression over on average 3.10 years were examined. RESULTS: Higher plasma p-tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p-tau217 in cognitively impaired individuals (β = -0.49, p < 0.001). Hypertension was further linked to... (More)

INTRODUCTION: We evaluated associations between phosphorylated au 217 (p-tau217), p-tau181, p-tau231, and vascular risk factors with cognitive outcomes across the Alzheimer's disease (AD) continuum. METHODS: Baseline plasma p-tau concentrations and vascular risk factors were assessed in 277 Consortium for the Early Identification of Alzheimer's Disease–Quebec (CIMA-Q) participants. Associations between these markers, cognition, and clinical progression over on average 3.10 years were examined. RESULTS: Higher plasma p-tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p-tau217 in cognitively impaired individuals (β = -0.49, p < 0.001). Hypertension was further linked to steeper memory and executive function decline (β = −0.10, both p = 0.04) in this group, and it amplified the effect of p-tau217 on cognitive decline across the whole group. Higher p-tau217 levels were associated with cognitive decline in cognitively unimpaired individuals, and it also predicted progression from mild cognitive impairment (MCI) to AD dementia (hazard ratio [HR] = 1.22, p = 0.016). DISCUSSION: Plasma p-tau217 was the most sensitive marker of cognitive decline, with hypertension contributing to longitudinal cognitive changes.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, clinical progression, cognition, hypertension, longitudinal, mild cognitive impairment, p-tau217
in
Alzheimer's and Dementia
volume
22
issue
6
article number
e71588
publisher
Wiley
external identifiers
  • pmid:42273887
  • scopus:105041795124
ISSN
1552-5260
DOI
10.1002/alz.71588
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2026 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
id
ff9d1ebd-04bb-4098-8310-e49ba9153163
date added to LUP
2026-08-18 15:54:47
date last changed
2026-09-01 16:49:56
@article{ff9d1ebd-04bb-4098-8310-e49ba9153163,
  abstract     = {{<p>INTRODUCTION: We evaluated associations between phosphorylated au 217 (p-tau217), p-tau181, p-tau231, and vascular risk factors with cognitive outcomes across the Alzheimer's disease (AD) continuum. METHODS: Baseline plasma p-tau concentrations and vascular risk factors were assessed in 277 Consortium for the Early Identification of Alzheimer's Disease–Quebec (CIMA-Q) participants. Associations between these markers, cognition, and clinical progression over on average 3.10 years were examined. RESULTS: Higher plasma p-tau levels were associated with worse cognition at baseline and over time, with the strongest effect observed with p-tau217 in cognitively impaired individuals (β = -0.49, p &lt; 0.001). Hypertension was further linked to steeper memory and executive function decline (β = −0.10, both p = 0.04) in this group, and it amplified the effect of p-tau217 on cognitive decline across the whole group. Higher p-tau217 levels were associated with cognitive decline in cognitively unimpaired individuals, and it also predicted progression from mild cognitive impairment (MCI) to AD dementia (hazard ratio [HR] = 1.22, p = 0.016). DISCUSSION: Plasma p-tau217 was the most sensitive marker of cognitive decline, with hypertension contributing to longitudinal cognitive changes.</p>}},
  author       = {{Cottez, Rosalie J. and Peyrot, Clémence and Denis, Hélèna L. and Tremblay, Cyntia and Loiselle, Andréanne and Dallaire-Théroux, Caroline and Filali-Mouhim, Ali and Hébert, Sébastien S. and Leclerc, Nicole and Blennow, Kaj and Zetterberg, Henrik and Kergoat, Marie Jeanne and Calon, Frédéric and Pichet Binette, Alexa}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; clinical progression; cognition; hypertension; longitudinal; mild cognitive impairment; p-tau217}},
  language     = {{eng}},
  number       = {{6}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Plasma p-tau markers, vascular factors, and cognitive decline in the CIMA-Q cohort}},
  url          = {{http://dx.doi.org/10.1002/alz.71588}},
  doi          = {{10.1002/alz.71588}},
  volume       = {{22}},
  year         = {{2026}},
}